ArticleNature2023
Antibodies against endogenous retroviruses promote lung cancer immunotherapy.
RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 160 papers.
0numbers the graph read from it
0cells of the map it votes in
160citing papers in PubMed
39.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
160 citing papers in PubMed, 245 citations in OpenAlex.
- Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.Nature communications · 2025Trial
- Mapping the functional dark proteome in cancer.Nature reviews. Cancer · 2026Review
- B cells in cancer: functions, mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- Activation of transposable elements is linked to a region- and cell type-specific interferon response in Parkinson's disease.Science advances · 2026Article
- Effect of Tertiary Lymphoid Structures on Immune Cell Infiltration in the Tumor Microenvironment and Prognosis in Lung Adenocarcinoma.Cancer medicine · 2026Article
- The RNA-Binding Protein PARN Remodeled 3' UTR Structure Defines Poly(A)-Loading Sites to Mediate Immunoglobulin Homeostasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Single-cell profiling of natural killer/T-cell lymphoma reveals stratified immune features and potential therapeutic implications.Nature communications · 2026Article
- The formation and function of tertiary lymphoid structures.Biomarker research · 2026Review
- Beyond the chaos: How architecture structures tumour biology.The FEBS journal · 2026Review
- Betrixaban activates cGAS and ERVs to promote dual nucleic-sensing antiviral immunity.EMBO molecular medicine · 2026Article
- Whole-proteome phage immunoprecipitation sequencing reveals germ cell tumor-specific immunosignature.Nature communications · 2026Article
- Single-cell and spatial transcriptome profiling identifies cellular heterogeneity and immunosuppressive tumor microenvironment in inflammatory breast cancer.Journal of advanced research · 2026Article
- Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade.Nature medicine · 2026Article
- Analysis of HERV-K (HML2) Expression in Colorectal Cancer Samples.Epigenomes · 2026Article
- Viral mimicry acts as a tumor suppressor in colitis.Nature communications · 2026Article
- TEITbase: a database for transposable element (TE)-initiated transcripts in human cancers.Database : the journal of biological databases and curation · 2026Article
- CDK9 Inhibition with enitociclib reveals influence on HERV and LINE RNA abundances in whole blood, T-, and B-Cell lines.BMC medical genomics · 2026Article
- TE-SCALE: a comprehensive database for exploring transposable element expression across human cancers at single-cell resolution.Nucleic acids research · 2026Article
- HERV-K TM Subunit Elicits CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Human endogenous retrovirus profiling reveals heterogenous expression in cutaneous melanoma.Frontiers in oncology · 2026Article
100 more citing papers are in PubMed but not listed here.
Corrections and comments
- Retraction · 2026-01-14Investigation by Company/Institution · Manipulation of Data · Unreliable Results and/or Conclusions · · see also: https://www.crick.ac.uk/about-us/our-approach-to-science/research-integrity/2025-research-integrity-news; Kevin W Ng assigned responsibility for manipulation of data;
- Commented on by
- Retracted
Authors and funding
51 authors at 20 institutions in 11 countries.
Kevin W Ng *Retroviral Immunology Laboratory, The Francis Crick Institute, London, UK.
Jesse Boumelha *Oncogene Biology Laboratory, The Francis Crick Institute, London, UK.
Katey S S Enfield *Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-4551-6073
Jorge AlmagroAdult Stem Cell Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-0652-6447
Hongui ChaDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Oriol PichCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-1956-1882
Takahiro KarasakiCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0001-6863-2360
David A MooreCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Roberto SalgadoDepartment of Pathology, ZAS Hospitals, Antwerp, Belgium.ORCID http://orcid.org/0000-0002-1110-3801
Monica SivakumarCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
George YoungRetroviral Immunology Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-1203-588X
Miriam Molina-ArcasOncogene Biology Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-8176-8948
Sophie de Carné TrécessonOncogene Biology Laboratory, The Francis Crick Institute, London, UK.
Panayiotis AnastasiouOncogene Biology Laboratory, The Francis Crick Institute, London, UK.
Annika FendlerCancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
Lewis AuCancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
Scott T C ShepherdCancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
Carlos Martínez-RuizCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Clare PuttickCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
James R M BlackCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Thomas B K WatkinsCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Hyemin KimDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Seohee ShimDepartment of Health Sciences and Technology, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea.
Nikhil FaulknerRetroviral Immunology Laboratory, The Francis Crick Institute, London, UK.
Jan AttigRetroviral Immunology Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-2159-2880
Selvaraju VeeriahCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Neil MagnoCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Sophia WardCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-6777-5279
Alexander M FrankellCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-0341-7878
Maise Al BakirCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-0846-8332
Emilia L LimCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Mark S HillCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-0718-8934
Gareth A WilsonCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Daniel E CookCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-3347-562X
Nicolai J BirkbakCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-1613-9587
Axel BehrensAdult Stem Cell Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-1557-1143
Nadia YousafRenal and Skin Units, The Royal Marsden Hospital, London, UK.
Sanjay PopatLung Unit, The Royal Marsden Hospital, London, UK.ORCID http://orcid.org/0000-0003-2087-4963
Allan HackshawCancer Research UK and University College London Cancer Trials Centre, London, UK.ORCID http://orcid.org/0000-0002-5570-5070
TRACERx Consortium
CAPTURE Consortium
Crispin T HileyCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Kevin LitchfieldCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-3725-0914
Nicholas McGranahanCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-9537-4045
Mariam Jamal-HanjaniCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
James LarkinRenal and Skin Units, The Royal Marsden Hospital, London, UK.
Se-Hoon LeeDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0002-9219-3350
Samra TurajlicCancer Dynamics Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0001-8846-136X
Charles SwantonCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. charles.swanton@crick.ac.uk.ORCID http://orcid.org/0000-0002-4299-3018
Julian DownwardOncogene Biology Laboratory, The Francis Crick Institute, London, UK. julian.downward@crick.ac.uk.ORCID http://orcid.org/0000-0002-2331-4729
George KassiotisRetroviral Immunology Laboratory, The Francis Crick Institute, London, UK. george.kassiotis@crick.ac.uk.ORCID http://orcid.org/0000-0002-8457-2633
The Francis Crick Institute · GBCancer Research UK · GBLondon Cancer · GBRoyal London Hospital · GBGuy's and St Thomas' NHS Foundation Trust · GBRoyal Marsden NHS Foundation Trust · GBManchester University NHS Foundation Trust · GBInstitute of Cancer Research · GBUniversity Hospitals of Leicester NHS Trust · GBUniversity Hospitals Birmingham NHS Foundation Trust · GBUniversity of Leicester · GBUniversity Hospital Southampton NHS Foundation Trust · GBRoyal Marsden Hospital · GBGolden Jubilee National Hospital · GBUniversity College London · GBAberdeen Royal Infirmary · GBUniversity College Hospital · GBUniversity of Manchester · GBAarhus University · DKCancer Research UK Manchester Centre
Funding
Cancer Research UK 17786Cancer Research UK 21999Cancer Research UK 24956Cancer Research UK 29569Cancer Research UK 29911Cancer Research UK 30025Cancer Research UK CTRNBC-2022/100001Medical Research Council MR/P014712/1Medical Research Council MR/V033077/1Wellcome Trust CC2041Wellcome Trust CC2044Wellcome Trust CC2088Wellcome Trust CC2097
Abstract
B cells are frequently found in the margins of solid tumours as organized follicles in ectopic lymphoid organs called tertiary lymphoid structures (TLS)
Indexed as
Endogenous RetrovirusesImmunotherapyLung NeoplasmsAdenocarcinoma of LungAnimalsAntibodiesB-LymphocytesCarcinoma, Non-Small-Cell LungChemokine CXCL13Cohort StudiesDisease Models, AnimalHumansLungMiceProto-Oncogene Proteins p21(ras)Tumor MicroenvironmentAntibodiesChemokine CXCL13Cxcl13 protein, mouseHras protein, mouseProto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.